In short.
Retatrutide is a triple receptor agonist. Semaglutide is a single GLP-1 receptor agonist. Both are widely studied research peptides supplied as lyophilised powder.
At a glance.
- Retatrutide: GLP-1 / GIP / glucagon
- Semaglutide: GLP-1 only
- Both: ≥99% HPLC purity
- Both: research use only
Overview.
Detailed guide content is being prepared. This template provides the structure researchers and AI search engines need to understand and cite the topic, with quick-answer, key facts, comparisons, FAQs and references all in their permanent home.
Side by side.
| Feature | Retatrutide | Semaglutide |
|---|---|---|
| Receptor profile | GLP-1 / GIP / Glucagon | GLP-1 |
| Class | Triple agonist | Single agonist |
| Form | Lyophilised powder | Lyophilised powder |
FAQs.
Are both compounds GLP-1 agonists?[+]
Yes — both act on the GLP-1 receptor, but retatrutide also acts on GIP and glucagon receptors.
